Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma

Abstract

More effective treatments are needed for low-grade serous ovarian carcinoma (LGSOC). Our patient, who suffers from metastatic LGSOC, had received all established treatments. Sequencing analysis revealed an activating BRAF mutation. Therefore, combined treatment with BRAF and MEK inhibitors, which is the gold standard in malignant melanoma, was initiated. After eight months of therapy, the response was assessed as complete and the treatment is still, 3.5 years after initiation, of benefit. To our knowledge, no complete response on combined BRAF and MEK inhibitor treatment of low-grade serous ovarian cancer has previously been reported.

Keywords:

• BRAF inhibitor
• chemotherapy
• low-grade serous ovarian cancer
• MEK inhibitor
• next-generation sequencing
• surgery
• targeted therapy
• V600E mutation

Acknowledgements

The authors are grateful to Pierre Fabre for supplying encorafenib and binimetinib without costs.

Disclosure statement

The authors declare that there are no conflicts of interest.